Quick Answer
TriSalus Life Sciences, Inc. reported Long-Term Debt of $33.05 million for fiscal year 2025.
TriSalus Life Sciences, Inc. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2025 | $33.05M | +49.6% |
| 2024 | $22.08M | — |
| 2023 | $0.00 | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $32.76M | +51.1% | +1.5% |
| June 30, 2025 | $32.27M | +51.6% | +1.8% |
| March 31, 2025 | $31.70M | — | +43.5% |
| December 31, 2024 | $22.08M | — | +1.9% |
| September 30, 2024 | $21.68M | — | +1.8% |
| June 30, 2024 | $21.29M | — | — |
| December 31, 2023 | $0.00 | — | — |
- TriSalus Life Sciences, Inc. showed an increase of +49.6% in Long-Term Debt compared to the prior fiscal year.
- The most recent figure is from TriSalus Life Sciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: